Atlas Venture Life Science Advisors, LLC Q3 2022 Filing

Filed November 9, 2022

Portfolio Value

$906.2B

Holdings

17

Report Date

Q3 2022

Filing Type

13F-HR

All Holdings (17 positions)

#StockSharesValue% PortfolioType
1
THRDThird Harmonic Bio, Inc.
10,907,859$206.9B22.83%
2
DAWNDay One Biopharmaceuticals, Inc.
8,169,171$163.6B18.06%
3
KYMRKymera Therapeutics, Inc.
6,875,698$149.7B16.52%
4
DYNDyne Therapeutics, Inc.
8,934,902$113.5B12.52%
5
REPLReplimune Group, Inc.
3,108,300$53.7B5.92%
6
VIGLVigil Neuroscience, Inc.
5,836,874$53.1B5.86%
7
GBIOGBXGeneration Bio, Co.
8,278,876$44.0B4.85%
8
AVTEAerovate Therapeutics, Inc.
2,327,909$38.6B4.26%
9
AKROAkero Therapeutics, Inc.
994,251$33.9B3.74%
10
Ikena Oncology, Inc.
5,018,178$17.8B1.97%
11
Gemini Therapeutics, Inc.
5,254,365$8.6B0.95%
12
XLOXilio Therapeutics, Inc.
2,759,344$8.0B0.89%
13
Magenta Therapeutics, Inc.
3,476,536$4.9B0.54%
14
F-star Therapeutics, Inc.
599,524$3.1B0.34%
15
AvroBio, Inc.
4,520,863$2.9B0.32%
16
SPROSpero Therapeutics, Inc.
1,031,160$2.1B0.23%
17
VRDNViridian Therapeutics, Inc.
90,072$1.8B0.20%